Twitter | Search | |
GenomeWeb
Highlighting the best of GenomeWeb's coverage of the genomics sector. Maintained by Bernadette Toner, CEO.
3,503
Tweets
640
Following
16,628
Followers
Tweets
GenomeWeb Sep 5
GenomeWeb has a new home! We've been acquired by - a great family of business journalism brands. We look forward to working with the Crain team to better serve our readers' news and information needs!
Reply Retweet Like
GenomeWeb Sep 4
A VHA program is making precision oncology a relatively routine part of cancer care for many veterans
Reply Retweet Like
GenomeWeb Jul 30
An official from the CancerLinQ database says labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.
Reply Retweet Like
GenomeWeb Jul 23
What is the clinical value of cell-free DNA testing in ? Professor Nicolaides of King’s College will discuss different implementation models & share his own experience with testing for fetal during our 7/25 webinar
Reply Retweet Like
GenomeWeb retweeted
Hologic Jul 18
Why are molecular assays the smartest choice for screening? Watch the free webinar and find out why when Dr. Pride presents the results of his recent publication comparing molecular to culture. Register today!
Reply Retweet Like
GenomeWeb retweeted
Yaolin Zhou, MD Jul 22
Reply Retweet Like
GenomeWeb Jul 22
How are top cancer centers implementing precision oncology? Our sister site sought to find out with this survey:
Reply Retweet Like
GenomeWeb Jul 17
GenomeWeb is hiring! We're looking for an experienced biopharma reporter for our new site, Precision Oncology News. More info here:
Reply Retweet Like
GenomeWeb Jun 20
Some diagnostic test kits marketed for home use are raising the eyebrows of lab experts worried about their safety to consumers and questioning whether they may be violating FDA regulations.
Reply Retweet Like
GenomeWeb retweeted
Illumina Live Events Jun 16
Register, today! Learn about the evidence supporting personal and clinical utility of polygenic risk profiling & how it can be transformative for clinical care as well as drug discovery. Register for this sponsored webinar here:
Reply Retweet Like
GenomeWeb Jun 17
At , researchers presented two new NIPT methods and a new way to determine recurrence risk for diseases caused by a de novo mutation.
Reply Retweet Like
GenomeWeb Jun 16
GenomeWeb is at booth #276 at . Stop by and say hello!
Reply Retweet Like
GenomeWeb Jun 6
TAPUR, an multi-basket trial, has reported data from two arms, demonstrating activity for palbociclib from and pembrolizumab from in biomarker-defined cancers. The study is also opening its first tissue-agnostic cohort.
Reply Retweet Like
GenomeWeb retweeted
PrecisionOncologyNews May 30
The commercial launch of two tissue-agnostic cancer drugs has energized the hunt for other targetable biomarkers present across tumor types and has oncologists thinking more about the biomarkers driving patients' tumors in addition to histology.
Reply Retweet Like
GenomeWeb May 30
The experience of and developing drugs for pan-cancer indications has piqued the interest of other pharma companies in this new paradigm. The also showed it can be flexible in the evidence it is willing to accept.
Reply Retweet Like
GenomeWeb retweeted
SOPHiA GENETICS May 22
We’re excited to announce our next webinar on , entitled “From Manual to Automated Library Prep: Implementation & Analytical Validation” presented by Dr. Dario Cacciadiferro from “Ospedale Pediatrico Bambin Gesù” Rome (IT). Please register here:
Reply Retweet Like
GenomeWeb May 23
If you're heading to next week, check out the abstract planning tool on our site or our sister site
Reply Retweet Like
GenomeWeb May 17
While reimbursement cuts driven by PAMA have taken center stage in many discussions of the difficulties facing the clinical lab business, the industry's ongoing staffing shortage is perhaps an even larger challenge.
Reply Retweet Like
GenomeWeb retweeted
PrecisionOncologyNews Apr 26
Cancer patients may benefit from personalized combination therapies rather than matched monotherapies, according to a new analysis from the Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) team.
Reply Retweet Like
GenomeWeb Apr 22
What complexities exist in incorporating the guidelines into treatment strategies? Find out during our sponsored webinar on 4/23
Reply Retweet Like